Application of Nanocomposites and Nanoparticles in Treating Neurodegenerative Disorders.

Javeria Fatima, Yasir Hasan Siddique
{"title":"Application of Nanocomposites and Nanoparticles in Treating Neurodegenerative Disorders.","authors":"Javeria Fatima, Yasir Hasan Siddique","doi":"10.2174/0118715273283338240104112106","DOIUrl":null,"url":null,"abstract":"<p><p>Neurodegenerative diseases represent a formidable global health challenge, affecting millions and imposing substantial burdens on healthcare systems worldwide. Conditions, like Alzheimer's, Parkinson's, and Huntington's diseases, among others, share common characteristics, such as neuronal loss, misfolded protein aggregation, and nervous system dysfunction. One of the major obstacles in treating these diseases is the presence of the blood-brain barrier, limiting the delivery of therapeutic agents to the central nervous system. Nanotechnology offers promising solutions to overcome these challenges. In Alzheimer's disease, NPs loaded with various compounds have shown remarkable promise in preventing amyloid-beta (Aβ) aggregation and reducing neurotoxicity. Parkinson's disease benefits from improved dopamine delivery and neuroprotection. Huntington's disease poses its own set of challenges, but nanotechnology continues to offer innovative solutions. The promising developments in nanoparticle-based interventions for neurodegenerative diseases, like amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), have offered new avenues for effective treatment. Nanotechnology represents a promising frontier in biomedical research, offering tailored solutions to the complex challenges posed by neurodegenerative diseases. While much progress has been made, ongoing research is essential to optimize nanomaterial designs, improve targeting, and ensure biocompatibility and safety. Nanomaterials possess unique properties that make them excellent candidates for targeted drug delivery and neuroprotection. They can effectively bypass the blood-brain barrier, opening doors to precise drug delivery strategies. This review explores the extensive research on nanoparticles (NPs) and nanocomposites in diagnosing and treating neurodegenerative disorders. These nanomaterials exhibit exceptional abilities to target neurodegenerative processes and halt disease progression.</p>","PeriodicalId":93947,"journal":{"name":"CNS & neurological disorders drug targets","volume":" ","pages":"1217-1233"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CNS & neurological disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0118715273283338240104112106","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Neurodegenerative diseases represent a formidable global health challenge, affecting millions and imposing substantial burdens on healthcare systems worldwide. Conditions, like Alzheimer's, Parkinson's, and Huntington's diseases, among others, share common characteristics, such as neuronal loss, misfolded protein aggregation, and nervous system dysfunction. One of the major obstacles in treating these diseases is the presence of the blood-brain barrier, limiting the delivery of therapeutic agents to the central nervous system. Nanotechnology offers promising solutions to overcome these challenges. In Alzheimer's disease, NPs loaded with various compounds have shown remarkable promise in preventing amyloid-beta (Aβ) aggregation and reducing neurotoxicity. Parkinson's disease benefits from improved dopamine delivery and neuroprotection. Huntington's disease poses its own set of challenges, but nanotechnology continues to offer innovative solutions. The promising developments in nanoparticle-based interventions for neurodegenerative diseases, like amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), have offered new avenues for effective treatment. Nanotechnology represents a promising frontier in biomedical research, offering tailored solutions to the complex challenges posed by neurodegenerative diseases. While much progress has been made, ongoing research is essential to optimize nanomaterial designs, improve targeting, and ensure biocompatibility and safety. Nanomaterials possess unique properties that make them excellent candidates for targeted drug delivery and neuroprotection. They can effectively bypass the blood-brain barrier, opening doors to precise drug delivery strategies. This review explores the extensive research on nanoparticles (NPs) and nanocomposites in diagnosing and treating neurodegenerative disorders. These nanomaterials exhibit exceptional abilities to target neurodegenerative processes and halt disease progression.

纳米复合材料和纳米粒子在治疗神经退行性疾病中的应用。
神经退行性疾病是一项严峻的全球健康挑战,影响着数百万人的健康,给全球医疗保健系统带来沉重负担。阿尔茨海默氏症、帕金森氏症和亨廷顿氏症等疾病具有共同的特征,如神经元丧失、错误折叠蛋白聚集和神经系统功能障碍。治疗这些疾病的主要障碍之一是血脑屏障的存在,限制了治疗药物向中枢神经系统的输送。纳米技术为克服这些挑战提供了前景广阔的解决方案。在阿尔茨海默氏症方面,含有各种化合物的纳米粒子在防止淀粉样蛋白-β(Aβ)聚集和减少神经毒性方面显示出显著的前景。帕金森病可从改善多巴胺输送和神经保护中获益。亨廷顿氏病也带来了一系列挑战,但纳米技术不断提供创新的解决方案。基于纳米粒子的神经退行性疾病(如肌萎缩性脊髓侧索硬化症(ALS)和多发性硬化症(MS))干预技术的发展前景广阔,为有效治疗提供了新途径。纳米技术是生物医学研究领域前景广阔的前沿技术,可为神经退行性疾病带来的复杂挑战提供量身定制的解决方案。虽然已经取得了很大进展,但持续的研究对于优化纳米材料设计、提高靶向性、确保生物相容性和安全性至关重要。纳米材料具有独特的特性,使其成为靶向给药和神经保护的绝佳候选材料。它们能有效绕过血脑屏障,为精准给药策略打开了大门。本综述探讨了纳米颗粒(NPs)和纳米复合材料在诊断和治疗神经退行性疾病方面的广泛研究。这些纳米材料在针对神经退行性病变过程和阻止疾病进展方面表现出卓越的能力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信